How do pharma, biotech and medtech manufacturers improve production efficiency with lean manufacturing without compromising the validated state?
We implement lean manufacturing principles in regulated production environments: value stream mapping, OEE optimization, material flow and pull control, with every change secured through the change control system of the EU GMP Guide (EudraLex Volume 4). The essential factor is rarely the method, but the sequence relative to the validated state: anyone who plans lean measures first and only then checks whether they trigger revalidation under Annex 15 builds in the very delay that lean is meant to eliminate.
- Pharma
- Biotech
- MedTech
- IVD
Overview
What efficiency problems arise in regulated production environments?
Lean measures managed through the change control system of the EU GMP Guide · Value stream mapping, OEE and SMED secured against the validated state per Annex 15
Last updated: 2026-06-13
Lean manufacturing aims to eliminate waste and smooth material flow. In a GMP setting, this goal meets a validated state that every process change touches and that must be managed through the change control system of the EU GMP Guide (EudraLex Volume 4). These are the points where lean initiatives in regulated production typically lose their effect:
- Equipment downtime and performance losses are accepted as a given because no systematic OEE measurement (availability, performance, quality rate) exists. The actual equipment utilization remains invisible and therefore unmanageable.
- Changeover and cleaning operations are labor-intensive because batch changes in a GMP environment are tied to cleaning and changeover validation; without SMED logic, changeover time is treated as unavoidable instead of being separated into internal and external steps.
- Layout and material flow follow historically grown routes rather than the zone and airlock concept; transport and motion generate waste that stays hidden behind the documentation requirements.
- Lean measures fail because their impact on the validated state is assessed too late. A change to equipment, process parameter or layout can trigger revalidation under Annex 15, which, without an early risk assessment per ICH Q9, only surfaces shortly before implementation.
- The quality system per ICH Q10 explicitly provides for continual improvement, yet without linking lean measures to change control and CAPA, improvements remain isolated actions instead of part of a managed system.
Services
How we support you
Value Stream Mapping & Lean Diagnosis
Value stream mapping of the production area with quantification of the waste potential along the eight types of lean waste. Deliverable: documented current-state value stream map, prioritized improvement list and a business case per measure.
OEE Analysis & Equipment Optimization
Building a systematic OEE measurement from availability, performance and quality rate, together with root cause analysis of the loss sources. Deliverable: defined OEE metrics model with data collection and prioritized measures to reduce losses for each bottleneck asset.
SMED & Changeover Time Reduction
Analysis of changeover, cleaning and switchover operations using the SMED methodology (Single-Minute Exchange of Die) with separation of internal and external changeover steps in the GMP context. Deliverable: documented target changeover workflows and action list, aligned with cleaning and changeover validation.
Lean Layout & Material Flow Optimization
Redesign of production layout and material flow for minimal transport and motion waste while observing the GMP zone and airlock concept. Deliverable: layout and flow concept with justification of the material routes and assessment of the change control needs.
Pull Systems & Visual Management
Introduction of pull-based production control, kanban concepts for GMP material control and visual management boards. Deliverable: documented control concept with sequencing of batch runs and visualization of status and open actions.
Learn more →Linking Lean Measures to Change Control
Assessment of each lean measure against the validated state with an impact assessment per ICH Q9 and linkage to the change control system of the EU GMP Guide. Deliverable: a documented classification within change control for each measure, including clarification of any revalidation needs under Annex 15.
How we work together
What it comes down to
Lean manufacturing in a regulated environment rarely fails because of the method, and almost always because of the sequence relative to the validated state. A value stream analysis quickly reveals where transport, motion, waiting and overproduction generate waste, and an OEE baseline makes the losses per asset visible. Yet every measure that resolves a bottleneck merely shifts it to the next station if the material flow is not viewed as a whole, and it becomes a delay when its impact on the validated state is only assessed at implementation. That is why the impact assessment per ICH Q9 belongs at the start: it determines which measure runs through the change control system of the EU GMP Guide (EudraLex Volume 4) and whether it triggers revalidation under Annex 15, before effort flows into implementation.
This is exactly where we begin. We prioritize lean measures not only by efficiency gain, but by the ratio of impact to change control effort, and we link them to the quality system per ICH Q10 and the existing CAPA system. In this way, changeover time reduction via SMED, layout adjustment and pull control do not become isolated actions that fizzle out after the project ends, but managed improvements that appear as a strength in the surveillance audit rather than as an uncontrolled change. The early look at sequence shifts the effort to where corrections are cheap: into planning rather than into the inspection.
Our approach
Our approach
Step
Result
Lean Diagnosis & Value Stream Capture
Current-state value stream map of the area with named waste potential along the eight types of waste.
OEE Baseline
Defined OEE metrics model and a captured baseline for each bottleneck asset as the starting point for loss reduction.
Prioritization & Business Case
Prioritized action list with a business case and an early assessment of change control and revalidation needs per ICH Q9.
Implementation via Change Control
Lean measures managed through the change control system of the EU GMP Guide, with QA approval and clarified revalidation needs under Annex 15.
Anchoring in the Quality System
Measures, control concepts and metrics linked to ICH Q10 and the existing CAPA system rather than left as isolated actions.
Common pitfalls
Where projects commonly fail
Lean measures are implemented before their impact on the validated state is assessed.
A change to equipment, parameter or layout can trigger revalidation under Annex 15; if the impact assessment per ICH Q9 is only carried out shortly before implementation, the exact delay that lean is meant to eliminate is created.
Improvements bypass the change control system of the EU GMP Guide.
A process change without a documented assessment and QA approval becomes a finding in the inspection rather than progress, even when it has demonstrably improved efficiency.
OEE is captured without a clean definition of the loss categories.
If the measurement mixes planned downtime, changeover times and quality losses, the metric provides no reliable root cause, and measures target the wrong point instead of the actual bottleneck.
SMED is reduced to the machine while cleaning and changeover validation are left out.
In regulated production, cleaning and changeover release account for a large part of the changeover time; a changeover optimization that does not include these steps stays on paper.
Lean is treated as a one-off project rather than part of the quality system per ICH Q10.
Without linkage to change control and CAPA, the improvements fall back into old patterns after the project ends, because the structure that would carry them forward is missing.
FAQ
Frequently asked questions
Sources
- EU GMP Guide (EudraLex Volume 4) - primary text, including Change Control / Quality Change Management and Annex 15 (Qualification and Validation)
- ICH Q9 (Quality Risk Management) and ICH Q10 (Pharmaceutical Quality System) - primary text
- 21 CFR Part 211 (cGMP - finished pharmaceuticals)
- ISO 13485:2016 - Quality management systems for medical devices; EU 2017/745 (MDR), EU 2017/746 (IVDR)
- Entourage source material on Lean Manufacturing (Manufacturing & Supply Chain)
- https://theentourage.de/expertise/lean-manufacturing/ (existing page content, revised)
Life Science Journal
Regulatory updates, straight to your inbox.
New requirements, authority decisions and practice notes. Once a month, unsubscribe any time.
Case Studies
What this looks like in practice
Related insights
All insights →Regulations & standards considered
- EU GMP Guide (EudraLex Volume 4)
- EU GMP Guide Part I (Medicinal Products for Human Use)
- EU GMP Guide (Change Control / Quality Change Management)
- EU GMP Guide Annex 15 (Qualification and Validation)
- ICH Q9 (Quality Risk Management)
- ICH Q10 (Pharmaceutical Quality System)
- 21 CFR Part 211 (cGMP for Finished Pharmaceuticals)
- ISO 13485:2016 (QMS for Medical Devices)
- EU 2017/745 (MDR)
- EU 2017/746 (IVDR)
Related topics
Lean Six Sigma →
Lean and Six Sigma combined when process variability also needs to be reduced
Production Transfer & Scale-Up →
Anchoring lean principles in the transfer and scale-up of new processes
Continuous Improvement Programs →
Anchoring lean measures permanently in the quality system per ICH Q10
Process Validation →
Revalidation needs under Annex 15 when lean touches the validated state
Have a concrete project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +49 89 4161170-0
info@theentourage.de
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences